Stefanos Zafeiropoulos, MD, MS, PhD (@Cardiaficionado) header
Stefanos Zafeiropoulos, MD, MS, PhD (@Cardiaficionado) profile picture

Physician-scientist 👨‍🎓👨‍⚕️| Fellow @CardioZurich | PhD @feinsteinIMR, @northwellhealth | MD, MSc @aristoteleio | Cardiovascular medicine 🫀|views are my own

New York, USA
Joined December 2014
Photo by Stefanos Zafeiropoulos, MD, MS, PhD (@Cardiaficionado)Photo by Stefanos Zafeiropoulos, MD, MS, PhD (@Cardiaficionado)Photo by Stefanos Zafeiropoulos, MD, MS, PhD (@Cardiaficionado)Photo by Stefanos Zafeiropoulos, MD, MS, PhD (@Cardiaficionado)Photo by Stefanos Zafeiropoulos, MD, MS, PhD (@Cardiaficionado)Photo by Stefanos Zafeiropoulos, MD, MS, PhD (@Cardiaficionado)Photo by Stefanos Zafeiropoulos, MD, MS, PhD (@Cardiaficionado)Photo by Stefanos Zafeiropoulos, MD, MS, PhD (@Cardiaficionado)Photo by Stefanos Zafeiropoulos, MD, MS, PhD (@Cardiaficionado)Photo by Stefanos Zafeiropoulos, MD, MS, PhD (@Cardiaficionado)
Stefanos Zafeiropoulos, MD, MS, PhD retweeted
A splash of colour (in every sense). In the age of Claude, ChatGPT, NotebookLM, and who knows how many others, seeing the Lp(a)HORIZON slides bring back an old classic—the electric-blue background with white and yellow text, straight out of the 2000s—is truly heartwarming.
11
11
1
164
9,970
🎙️ Στο νέο επεισόδιο του CardioBeans, συζητάμε με τον @GGiannakoulas & τον κ. Σαχινίδη για την παχυσαρκία και τους GLP-1 και GLP-1/GIP αγωνιστές. Τι γνωρίζουμε για τα οφέλη στην καρδιά και τους νεφρούς, την ασφάλεια και τη διατήρηση του αποτελέσματος open.spotify.com/episode/1lb…
1
1
194
Stefanos Zafeiropoulos, MD, MS, PhD retweeted
Hi all, The Lp(a) HORIZON trial has released topline data and, quite shockingly, missed its primary endpoint. In other words, lowering Lp(a) in patients with prior MI, stroke or peripheral arterial disease, who were otherwise very well treated for LDL-C, blood pressure, diabetes and other risk factors, did not reduce the primary cardiovascular endpoint. We obviously need to see the full data before making firm conclusions, and I don’t want to speculate too much without the details. But this is a big enough result that it is worth summarizing what we know, what we don’t know, and what this may mean for our patients after 20+ years of trying to test the “Lp(a) hypothesis.” What we know: 1-There are hundreds if not thousands of genetic, epidemiologic and Mendelian-randomization studies showing that elevated Lp(a) is associated with MI, stroke, peripheral arterial disease and aortic stenosis. That body of evidence is very strong. 2-However, much of those data come from community-based populations, often before the era of intensive LDL-C lowering and modern secondary prevention. 3-There has been much less information about how much residual risk Lp(a) carries in someone who has already had an event and is then treated very aggressively. 4-HORIZON may have had some of the best-treated patients of any recent cardiovascular outcomes trial. Baseline LDL-C was about 65 mg/dL, a measured LDL-C contains the cholesterol carried on Lp(a), so in reality, 15-20 points lower. 5-In patients with very high Lp(a), if you correct LDL-C for Lp(a)-cholesterol, the actual LDL-C carried by LDL particles may have been closer to 45–50 mg/dL, perhaps even lower in some patients. 6-This raises a very basic question: Can you still demonstrate a major incremental benefit from lowering another apoB-containing particle when the underlying LDL burden has already been driven this low? What we don’t know: 1-What was the actual corrected LDL-C in these patients? I think it would be extremely informative to directly measure Lp(a)-C and calculate corrected LDL-C. This may tell us a lot about the biological setting in which pelacarsen was being tested. 2- What was the OxPL status? Our prior work has suggested that much of the pro-inflammatory biology associated with Lp(a) is related to its enrichment in oxidized phospholipids. Did OxPL fall? Did patients with higher OxPL derive more benefit? Was Lp(a) concentration actually identifying the patients with the most pathogenic particles? 3- Did we measure the right component of Lp(a) for trial inclusion? We generally measure molar particle concentration. But is molar concentration itself the main driver of risk, or is it partly a surrogate for what the particle carries? Cholesterol? Triglycerides? Oxidized phospholipids? Other proteins? Could two patients with the same Lp(a) concentration have very different Lp(a)-mediated risk? I think this question deserves much more attention. 3- Were the genetic data telling us exactly what we thought they were telling us? The genetic data are extremely compelling, but genetics reflect lifelong exposure. A clinical trial treats patients late in life, often after decades of arterial injury and after an event has already occurred. Those are not necessarily the same experiment. Could there also be some unrecognized biology linked to the LPA locus that we have not completely accounted for? That possibility should at least be considered. 3- Does very low LDL-C modify the Lp(a) risk relationship? Maybe Lp(a) is particularly important when LDL-C is higher, but its contribution becomes smaller once LDL-C is driven to very low levels. Again, we need the data. 4- Does aspirin or other antiplatelet therapy reduce part of the risk associated with Lp(a)? Lp(a) has potentially important prothrombotic effects. Almost everyone in a trial like HORIZON is receiving contemporary antiplatelet therapy. Could that blunt one component of the risk associated with Lp(a)? 5- Why are these patients still having events? This may be one of the most interesting questions of all. These are patients with LDL-C around 65 mg/dL, and perhaps corrected LDL-C substantially lower, yet cardiovascular events continue to occur. What is driving that residual risk? Inflammation? Thrombosis? Plaque burden that is already too advanced? Other lipoprotein characteristics? Something we are not measuring? 6- Do we need to re-examine some basic assumptions about atherosclerosis? We have spent decades focusing heavily on the quantity of circulating lipoproteins. But perhaps lipoproteins are relatively benign until they undergo biological modification in the artery wall. Oxidation may be one of those key modifications. For some patients, the answer may be to remove more particles from the circulation. For others, perhaps the better approach is to prevent their oxidation or block the downstream biological effects of oxidized lipids. The recent difficulties with anti-inflammatory approaches, including IL-6 inhibition, make these mechanistic questions even more interesting. 7- Was there something specific about pelacarsen, the degree or timing of Lp(a) lowering, advanced disease, trial duration, background therapy or patient selection that mitigated a potential benefit? We simply don’t know yet. That is why the detailed results will be so important. What does this mean for patients today? If you have already had an MI, stroke or PAD, the immediate lesson is very clear: 1- Get all of your established risk factors treated aggressively. 2- Get LDL-C/apoB very low. 3- Control blood pressure. 4- Control diabetes. 5- Don’t smoke. 6- Use appropriate antiplatelet and other guideline-directed therapies. HORIZON shows us what modern secondary prevention should look like. If you have elevated Lp(a) but have never had an event, the genetic and epidemiologic data still suggest increased lifetime risk. Until the other 4 outcome trials read out, I would continue to treat every modifiable risk factor aggressively. We should wait for those trials before drawing broad conclusions about the entire field. I think the story of Lp(a) therapy is beginning, not ending. We also need to show tremendous respect and gratitude to the patients who participated in HORIZON and to the investigators and companies that invested enormous resources to actually test the Lp(a) hypothesis, to the ultimate benefit to peole with elevated Lp(a) to best guide how to manage risk. More to come as we go forward.
95
311
43
1,093
183,302
Nέο επεισόδιο Cardiobeans με τον Απόστολο Τζίκα! Συζητάμε τις τελευταίες εξελίξεις στη σύγκλειση του ωτίου αριστερού κόλπου (LAAO): OPTION, CHAMPION-AF και CLOSURE-AF, επιλογή ασθενών, νέες συσκευές και συνδυασμός με AF ablation.Kαλή ακρόαση @GGiannakoulas open.spotify.com/episode/2xW…
1
4
219
Οι συγγενείς καρδιοπάθειες δεν αφορούν πλέον μόνο τα παιδιά. Σε αυτό το επεισόδιο συζητάμε τις σημαντικότερες προκλήσεις, τις συχνότερες επιπλοκές και τις σύγχρονες εξελίξεις στη διάγνωση και τη θεραπεία. 🎧 Καλή ακρόαση! @GGiannakoulas #Cardiobeans #ACHD open.spotify.com/episode/4Qr…
2
5
326
Νέο επεισόδιο🎙️ Μαζί με τον @LKoliastasis συζητάμε τις εξελίξεις στη σύγχρονη επεμβατική καρδιολογία με έμφαση σε CHIP PCI & CTO επεμβάσεις: επιλογή ασθενών, απεικόνιση, φυσιολογία, κλινικά αποτελέσματα, εκπαίδευση & νέες τεχνολογίες. @GGiannakoulas open.spotify.com/episode/1PR…
2
3
123
Νέο επεισόδιο Cardiobeans podcast με τον Πρόδρομο Ανθόπουλο σχετικά με την Καρδιολογία μέσα από την οπτική της φαρμακοβιομηχανίας. Η προσωπική διαδρομή, το career transition & η συνεργασία μεταξύ κλινικών & φαρμακοβιομηχανίας. Καλή χρονιά & καλή ακρόαση! open.spotify.com/episode/6kC…
1
93
Stefanos Zafeiropoulos, MD, MS, PhD retweeted
NEW EPISODE OF THE LEAD! [Ep. 126] A Discussion of Transcutaneous Electrical Vagus Nerve Stimulation to Suppress Premature Ventricular Contractions: A Crossover, Randomized Clinical Trial (NoVa-PVC) 🎙️ Host: Sandeep A Saha, MD, MS, FHRS (@DrSSahaCardio) 🎤 Guests: Charles A. Henrikson, MD, MPH, FHRS and Arun R. Mahankali Sridhar, MBBS, MPH, FACC Listen on your preferred podcast platform ➡️ bit.ly/48bpxNn #EPeeps #medpod #podcast #CardioTwitter #EPTwitter #PodcastAndChill
3
6
728
Νέο επεισόδιο CardioBeans 🎙️ με καλεσμένη την καθηγήτρια Πνευμονολογιίας Aφροδίτη Μπούτου: 🤝 Η σημασία συνεργασίας καρδιολόγου-πνευμονολόγου ❤️‍🩹 Μείωση καρδιοπνευμονικού κινδύνου ⚠️ Συχνά λάθη που πρέπει να αποφύγουμε #CardioBeans @GGiannakoulas open.spotify.com/episode/22T…
1
1
126
Έχασες το ESC 2025; 🔥 Σ'αυτό το επεισόδιο του CardioBeans 🎙️ συζητάμε τις πιο hot μελέτες: DIGIT-HF, POTCAST, REBOOT & BETAMI–DANBLOCK, ALONE-AF, MAPLE-HCM, ODYSSEY-HCM & BaxHTN. Καλή ακρόαση! #CardioBeans #ESC2025 @GGiannakoulas open.spotify.com/episode/4io…
1
1
158
Stefanos Zafeiropoulos, MD, MS, PhD retweeted
#DIGIT_HF will change clinical practice for patients with #HFrEF ‼️ ⁦@ShelleyZieroth⁩ ⁦@DavidDuncker⁩ ⁦@escardio⁩ #ESCCongress2025 ⁦@YoungDgk⁩ ⁦@DGK_org⁩ ⁦@NEJM⁩
6
20
72
5,577
Stefanos Zafeiropoulos, MD, MS, PhD retweeted
Panathinaikos made one of the best player intros in history for Davide Calabria.
13
52
7
587
34,772
Stefanos Zafeiropoulos, MD, MS, PhD retweeted
I’m happy to have been a (small) part of this project. I’m even happier to see it published. Congratulations to @lsjMD for leading this incredible work.
Getting your real-time heart rhythm monitored for 10 days now requires an ECG technician to review and notify your doctor of a critical arrhythmia. A new study showed A.I. did better than technicians (98.6% vs 80.3%) for identifying these abnormalities nature.com/articles/s41591-0… @NatureMedicine
3
2
19
2,821
Stefanos Zafeiropoulos, MD, MS, PhD retweeted
Now online in @NatureMedicine DRAI MARTINI 🍸 👉🏻 Artificial intelligence #AI for direct-to-physician reporting of ambulatory electrocardiography… Such a privilege to work with this whole team. And thank you 🙏🏻 @lsjMD for your leadership in getting us all together. 📖 nature.com/articles/s41591-0… Once again thanks a lot for including me on this super project. Looking forward to the next! 🙂 @ManningerMartin @StavrosStavrak1 @AviSabbag @SZDiederichsen @PawelTMatusikMD @WFMMD @EmmaSvennberg @DrJasonAndrade
5
23
4
54
7,368
Πρώτο επεισόδιο του 2025🎙️ συζητάμε μαζί με τον κ. @AlAntonopoulos για την καρδιακή αμυλοείδωση. 1) Ποιοι είναι οι κύριοι τύποι; 2) Πως γίνεται η διάγνωση; 3) Σποραδική vs κληρονομική ATTR αμυλοδείδωση. 4) Ποιες οι θεραπείες; Καλή ακρόαση! @GGiannakoulas open.spotify.com/episode/029…
1
5
188
Νέο επεισόδιο CardioBeans podcast🎙️για το καρδιογενές σοκ 1) Ορισμός 2) Guidelines 3)Ποιες είναι οι θεραπείες για μηχανική υποστήριξη του κυκλοφορικού και ποτε έχουν ένδειξη; -Ενδοαρτικος ασκός -VA-ECMO -Impella -ECMELLA Καλή ακρόαση!🎧 @GGiannakoulas open.spotify.com/episode/35g…
1
7
330
I am excited about this new beginning as a research group leader, along with my clinical work, and looking forward to making an impact! Thank you @FrancescoPaneni for this opportunity!
We are thrilled to announce that Dr. Stefanos Zafeiropoulos will start his appointment as Research Group Leader at #CTEC. His lab will delve into the molecular and physiological aspects of autonomic regulation in cardiovascular physiology. We wish Stefanos a great start!
2
1
27
1,308
Stefanos Zafeiropoulos, MD, MS, PhD retweeted
We are thrilled to announce that Dr. Stefanos Zafeiropoulos will start his appointment as Research Group Leader at #CTEC. His lab will delve into the molecular and physiological aspects of autonomic regulation in cardiovascular physiology. We wish Stefanos a great start!
1
2
2
13
2,680
Valenti et al. presented a compelling case report of a young patient with 3rd-degree AV block who underwent cardioneuroablation targeting the inferior paraseptal ganglionated plexus and resulted in complete resolution of the 3rd-degree AV block and the patient's symptoms.
1
119
The research presented in this special issue marks a significant advancement in our understanding of the ANS's influence across the spectrum of arrhythmias, ranging from AF to ventricular arrhythmias & AV blocks. Thanks to the authors & reviewers for making this issue a success!
101